POET (POET) earns a BUY rating with a $21.14 price target representing 147% upside, driven by a $500 million Lumilens deal and Malaysia 800G production starting Q3 2026. Compared to profitable peers Lumentum (LITE) and Coherent (COHR), POET's 1,089 price-to-sales ratio makes the bull case entirely dependent on 2027 volume execution. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Poet Technologies didn't make the cut.
Grab the names FREE today. POET Technologies (NASDAQ:POET) is a leading AI photonics story on the Nasdaq with real momentum heading into earnings. A fortress balance sheet, marquee Lumilens contract, and Malaysia production ramp moving from plans to shipments create an asymmetric risk/reward.
Our 24/7 Wall St. price target for POET is $21.14, implying 146.96% upside from $8.56. Our recommendation is buy at medium confidence. POET shares are up 35.23% year to date and 55.92% over the past year, though trading 16% below the 52-week high of $20.81.
Q1 2026 revenue of $503,390 beat estimates by 44.66% and grew 201.9% year over year. The reported loss of $0.08 missed the $0.04 loss consensus as warrant gains normalized. Recent catalysts cut both ways.
A board refresh adding Dr. Bardia Pezeshki and Jean F. Rankin sent shares up 6.24% in early August.
Lumilens closing a $700 million funding round validated POET's largest customer relationship. Offsetting that: class action lawsuits tied to PFIC disclosures and the Celestial AI purchase order cancellation earlier this summer. POET expects to ship more than 30,000 optical engines in 2026, with high-volume 800G production beginning Q3 2026 at the Malaysia facility.
Extract — continue reading at the source.
